Cannabinoids In Multiple Sclerosis (CAMS) Study: Safety And Efficacy Data For 12 Months Follow Up
| Effect | None |
| Trial Design | Cohort |
| Trial Length | 6+ Months |
| Number of Subjects | 502 |
| Sex | Both Genders |
| Age Range | 45-64, 65+ |
| Body Types | Average |
Following the completion of the CAMS trial and following up patients who chose to maintain THC / cannabis / placebo treatment for up to a year, it was noted that the benefits towards self-reported muscular health persisted while benefits appeared (to a clinically mild degree) on Ashworth rating scales. Fatigue and Energy, but not irritability or depression, also appeared to be benefited after 27 and 52 weeks.
